Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1920 MCKINNEY AVENUE, 7TH FLOOR DALLAS TX 75201 |
Tel: | N/A |
Website: | https://www.lanternpharma.com |
IR: | See website |
Key People | ||
Panna L. Sharma President, Chief Executive Officer, Director | David R. Margrave Chief Financial Officer, Secretary | Kishor G. Bhatia Chief Scientific Officer | Marc Chamberlain Chief Medical Officer |
Business Overview |
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc. |
Financial Overview |
For the three months ended 31 March 2024, Lantern Pharma Inc revenues was not reported. Net loss increased 41% to $5.4M. Higher net loss reflects Other income, net decrease of 68% to $90K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.36 to -$0.51. |